Price
CHART BY
Frequently asked questions
What is Nektar's market capitalization?
The market capitalization of Nektar is $361.29M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Nektar?
Nektar's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$9.526. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Nektar's stock?
Currently, 8 analysts cover Nektar's stock, with a consensus target price of $90.67. Analyst ratings provide insights into the stock's expected performance.
What is Nektar's revenue over the trailing twelve months?
Over the trailing twelve months, Nektar reported a revenue of $87.25M.
What is the EBITDA for Nektar?
Nektar's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$136.62M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Nektar?
Nektar has a free cash flow of -$178.19M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Nektar have, and what sector and industry does it belong to?
Nektar employs approximately 61 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Nektar's shares?
The free float of Nektar is 11.96M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $361.29M
- EPS (TTM)
- -$9.526
- Free Float
- 11.96M
- Revenue (TTM)
- $87.25M
- EBITDA (TTM)
- -$136.62M
- Free Cashflow (TTM)
- -$178.19M
Pricing
- 1D span
- $27.19$33.76
- 52W span
- $6.498$37.33
Analyst Ratings
The price target is $90.67 and the stock is covered by 8 analysts.
Buy
6
Hold
1
Sell
1
Information
Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.
- Employees
- 61
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- ISIN
- US6402683063
- Primary Ticker
- NKTR
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet